Teladoc Health (TDOC) Financials

$6.98 +0.02 (+0.22%)

Closing price 05/29/2025 03:59 PM Eastern

Extended Trading

$6.98 -0.01 (-0.14%)

As of 05/29/2025 07:59 PM Eastern

Annual Income Statements for Teladoc Health

This table shows Teladoc Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-1,001	-220	-13,660	-429	-485	-99	-97	-107	-74	-58	-17
Consolidated Net Income / (Loss)	-1,001	-220	-13,660	-429	-485	-99	-97	-107	-74	-58	-17
Net Income / (Loss) Continuing Operations	-1,001	-220	-13,660	-429	-485	-99	-97	-107	-74	-58	-17
Total Pre-Tax Income	-994	-220	-13,663	-385	-576	-109	-97	-107	-74	-58	-17
Total Operating Income	-1,021	-249	-13,653	-266	-506	-80	-71	-75	-63	-56	-15
Total Gross Profit	1,818	1,842	1,663	1,382	703	369	289	172	91	56	34
Total Revenue	2,570	2,602	2,407	2,033	1,094	553	418	233	123	77	44
Operating Revenue	2,570	2,602	2,407	2,033	1,094	553	418	233	123	77	44
Total Cost of Revenue	751	760	744	650	391	184	129	62	32	21	9.93
Operating Cost of Revenue	751	760	744	650	391	184	129	62	32	21	9.93
Total Operating Expenses	2,839	2,091	15,316	1,648	1,210	449	360	247	154	112	49
Selling, General & Admin Expense	640	678	677	689	661	229	176	118	75	61	29
Marketing Expense	706	689	624	417	226	110	85	58	35	20	7.66
Research & Development Expense	307	349	334	312	165	65	54	34	22	14	7.57
Depreciation Expense	10	11	11	8.94	69	39	36	19	8.27	4.86	2.32
Amortization Expense	363	326	245	195	-	-	-	-	-	-	-
Impairment Charge	790	0.00	13,403	0.00	0.00	-	-	-	-	-	-
Restructuring Charge	22	38	23	27	88	6.62	10	13	6.96	0.55	0.20
Total Other Income / (Expense), net	27	29	-10	-119	-70	-29	-26	-32	-11	-2.20	-1.50
Interest Expense	24	22	22	125	69	29	26	17	2.59	2.20	1.50
Interest & Investment Income	57	47	13	0.78	-	-	-	-	-	-	-
Other Income / (Expense), net	-6.04	4.45	-0.86	5.09	-0.55	0.34	-	-14	-8.45	-	-
Income Tax Expense	7.59	0.76	-3.81	44	-91	-11	0.12	-0.23	0.51	0.04	0.39
Basic Earnings per Share	($5.87)	($1.34)	($84.60)	($2.73)	($5.36)	($1.38)	($1.47)	($1.93)	($1.75)	($2.91)	($10.25)
Weighted Average Basic Shares Outstanding	170.56M	164.58M	161.46M	156.94M	90.51M	71.84M	65.84M	55.43M	42.33M	19.92M	1.96M
Diluted Earnings per Share	($5.87)	($1.34)	($84.60)	($2.73)	($5.36)	($1.38)	($1.47)	($1.93)	($1.75)	($2.91)	($10.25)
Weighted Average Diluted Shares Outstanding	170.56M	164.58M	161.46M	156.94M	90.51M	71.84M	65.84M	55.43M	42.33M	19.92M	1.96M
Weighted Average Basic & Diluted Shares Outstanding	173.67M	167.04M	162.62M	160.33M	90.51M	71.84M	65.84M	55.43M	42.33M	19.92M	1.96M

This table shows Teladoc Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-93	-48	-33	-838	-82	-29	-57	-65	-69	-3,810	-73
Consolidated Net Income / (Loss)	-93	-48	-33	-838	-82	-29	-57	-65	-69	-3,810	-73
Net Income / (Loss) Continuing Operations	-93	-48	-33	-838	-82	-29	-57	-65	-69	-3,810	-73
Total Pre-Tax Income	-111	-48	-32	-834	-79	-25	-60	-66	-69	-3,812	-75
Total Operating Income	-121	-48	-44	-841	-87	-35	-65	-72	-77	-3,816	-72
Total Gross Profit	433	452	461	454	452	467	474	462	439	449	426
Total Revenue	629	640	641	642	646	661	660	652	629	638	611
Operating Revenue	629	640	641	642	646	661	660	652	629	638	611
Total Cost of Revenue	197	189	180	188	195	193	186	191	190	189	186
Operating Cost of Revenue	197	189	180	188	195	193	186	191	190	189	186
Total Operating Expenses	553	500	505	1,296	539	502	539	534	516	4,264	498
Selling, General & Admin Expense	161	153	162	160	166	162	168	179	169	176	167
Marketing Expense	168	175	177	170	183	147	186	179	177	146	179
Research & Development Expense	70	77	72	77	81	90	84	87	87	83	85
Depreciation Expense	3.56	2.98	2.67	1.70	2.83	2.79	2.47	2.95	2.92	-169	62
Amortization Expense	84	87	87	95	95	95	92	73	67	-	-
Impairment Charge	59	-	0.00	790	-	-	0.00	0.00	-	3,773	0.00
Restructuring Charge	6.54	6.06	4.04	1.96	10	5.16	6.24	13	14	10	5.27
Total Other Income / (Expense), net	9.34	-5.60	12	13	7.92	9.71	5.17	5.52	8.56	3.64	-2.92
Interest Expense	5.77	-	5.66	-	5.65	5.54	5.65	5.84	5.26	4.75	6.15
Interest & Investment Income	13	14	15	14	14	14	13	12	8.91	-	4.80
Other Income / (Expense), net	2.44	-7.34	2.24	-0.56	-0.37	1.54	-1.79	-0.21	4.91	1.75	-1.57
Income Tax Expense	-18	0.24	0.78	3.88	2.69	3.52	-2.48	-0.95	0.68	-1.84	-1.17
Basic Earnings per Share	($0.53)	($0.27)	($0.19)	($4.92)	($0.49)	($0.17)	($0.35)	($0.40)	($0.42)	($23.35)	($0.45)
Weighted Average Basic Shares Outstanding	174.15M	170.56M	171.50M	170.23M	167.73M	164.58M	165.12M	164.17M	162.92M	161.46M	161.73M
Diluted Earnings per Share	($0.53)	($0.27)	($0.19)	($4.92)	($0.49)	($0.17)	($0.35)	($0.40)	($0.42)	($23.35)	($0.45)
Weighted Average Diluted Shares Outstanding	174.15M	170.56M	171.50M	170.23M	167.73M	164.58M	165.12M	164.17M	162.92M	161.46M	161.73M
Weighted Average Basic & Diluted Shares Outstanding	175.43M	173.67M	172.17M	171.22M	169.59M	167.04M	165.56M	164.95M	163.67M	162.62M	161.93M

This table details how cash moves in and out of Teladoc Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	178	205	28	162	215	90	383	-7.39	-5.05	8.63	43
Net Cash From Operating Activities	294	350	189	194	-54	30	-4.86	-34	-52	-47	-11
Net Cash From Continuing Operating Activities	294	350	189	194	-54	30	-4.86	-34	-52	-47	-11
Net Income / (Loss) Continuing Operations	-1,001	-220	-13,660	-429	-485	-99	-97	-107	-74	-58	-17
Consolidated Net Income / (Loss)	-1,001	-220	-13,660	-429	-485	-99	-97	-107	-74	-58	-17
Depreciation Expense	10	11	11	12	71	39	36	19	8.27	4.86	2.32
Amortization Expense	373	338	256	207	6.90	6.00	0.00	14	7.72	-	-
Non-Cash Adjustments To Reconcile Net Income	950	212	13,637	405	534	96	60	39	10	6.37	1.95
Changes in Operating Assets and Liabilities, net	-37	9.74	-56	-2.19	-181	-12	-3.38	0.41	-4.04	-0.39	1.41
Net Cash From Investing Activities	-124	-156	-168	-73	-591	25	-257	-448	26	-108	-16
Net Cash From Continuing Investing Activities	-124	-156	-168	-73	-591	25	-257	-448	26	-108	-16
Purchase of Property, Plant & Equipment	-124	-156	-173	-64	-26	-3.51	-4.01	-2.63	-2.11	-6.28	-1.07
Sale and/or Maturity of Investments	0.00	0.00	2.51	61	2.50	47	84	86	111	20	-
Other Investing Activities, net	0.00	0.00	2.51	8.72	0.00	0.00	-	-	-	-	-
Net Cash From Financing Activities	8.31	11	6.50	41	859	35	646	475	21	164	70
Net Cash From Continuing Financing Activities	8.31	11	6.50	41	859	35	646	475	21	164	70
Repayment of Debt	-0.00	-0.28	-5.89	-5.07	-34	0.00	0.00	-226	-17	-6.33	-
Issuance of Common Equity	4.75	9.65	6.50	17	4.72	3.38	333	261	0.25	163	-
Other Financing Activities, net	3.57	1.48	5.88	29	117	32	33	177	2.60	0.43	0.75
Cash Interest Paid	17	17	17	19	15	12	10	9.45	2.39	2.00	1.19
Cash Income Taxes Paid	8.95	7.24	2.51	3.97	1.32	1.31	0.44	0.14	-	-	-

This table details how cash moves in and out of Teladoc Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-107	58	80	65	-25	92	73	69	-29	16	22
Net Cash From Operating Activities	16	86	110	89	8.92	130	106	101	13	66	63
Net Cash From Continuing Operating Activities	16	86	110	89	8.92	130	106	101	13	66	63
Net Income / (Loss) Continuing Operations	-93	-48	-33	-838	-82	-29	-57	-65	-69	-3,810	-73
Consolidated Net Income / (Loss)	-93	-48	-33	-838	-82	-29	-57	-65	-69	-3,810	-73
Depreciation Expense	3.56	2.98	2.67	1.70	2.83	2.79	2.47	2.95	2.92	-171	63
Amortization Expense	87	89	89	97	98	98	94	75	70	247	2.73
Non-Cash Adjustments To Reconcile Net Income	86	34	38	834	44	43	57	59	53	3,825	63
Changes in Operating Assets and Liabilities, net	-67	8.99	14	-6.62	-54	16	8.80	29	-44	-26	7.88
Net Cash From Investing Activities	-123	-30	-31	-28	-36	-37	-38	-37	-46	-54	-41
Net Cash From Continuing Investing Activities	-123	-30	-31	-28	-36	-37	-38	-37	-46	-54	-41
Purchase of Property, Plant & Equipment	-32	-30	-31	-28	-36	-37	-38	-37	-46	-54	-43
Acquisitions	-65	-	-	-	-	-	-	-	-	-	-
Purchase of Investments	-27	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	0.77	2.06	0.70	3.81	1.75	-1.78	5.07	4.21	3.35	4.38	0.63
Net Cash From Continuing Financing Activities	0.77	2.06	0.70	3.81	1.75	-1.78	5.07	4.21	3.35	4.38	0.63
Repayment of Debt	0.00	-	-	-	-0.00	-0.28	0.00	0.17	-0.17	1.62	-1.99
Issuance of Common Equity	0.69	1.03	0.92	1.28	1.52	1.05	3.16	2.70	2.73	3.12	1.41
Other Financing Activities, net	0.08	1.03	-0.23	2.52	0.24	-2.55	1.91	1.34	0.79	-0.36	1.21
Cash Income Taxes Paid	0.33	1.71	2.62	4.86	-0.25	0.92	5.53	0.44	0.35	1.61	0.34

This table presents Teladoc Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	3,517	4,392	4,345	17,735	17,755	1,603	1,529	824	304	230	92
Total Current Assets	1,664	1,489	1,315	1,225	1,060	588	533	156	83	152	54
Cash & Equivalents	1,298	1,124	918	893	733	514	424	43	50	55	46
Accounts Receivable	214	217	211	169	169	57	44	27	14	12	6.84
Inventories, net	38	30	56	73	56	0.00	-	-	-	-	-
Prepaid Expenses	113	118	130	87	47	14	11	6.84	3.10	2.10	0.97
Plant, Property, & Equipment, net	29	32	30	27	29	10	10	8.96	7.48	6.26	1.07
Total Noncurrent Assets	1,823	2,871	3,000	16,482	16,667	1,005	986	659	213	72	36
Goodwill	283	1,073	1,073	14,504	14,581	746	737	499	188	56	28
Intangible Assets	1,431	1,678	1,837	1,910	2,021	225	247	160	25	15	7.53
Other Noncurrent Operating Assets	109	120	90	67	65	33	1.40	0.86	0.42	0.29	0.30
Total Liabilities & Shareholders' Equity	3,517	4,392	4,345	17,735	17,755	1,603	1,529	824	304	230	92
Total Liabilities	2,025	2,066	2,038	1,680	1,871	589	516	265	73	51	39
Total Current Liabilities	942	421	400	331	333	90	62	40	21	18	10
Short-Term Debt	551	0.00	-	-	43	0.00	-	-	2.00	1.25	0.83
Accounts Payable	33	44	48	47	46	9.08	7.77	3.88	2.24	2.21	2.21
Accrued Expenses	202	179	169	103	84	34	27	19	7.98	8.20	3.92
Current Deferred Revenue	79	96	102	76	52	12	-	-	-	-	-
Current Employee Benefit Liabilities	76	103	82	92	95	34	28	17	8.86	6.33	3.36
Total Noncurrent Liabilities	1,084	1,646	1,638	1,349	1,539	499	453	225	52	33	28
Long-Term Debt	991	1,539	1,535	1,226	1,380	440	415	207	42	25	25
Capital Lease Obligations	32	43	38	-	43	25	-	-	-	-	-
Noncurrent Deferred Revenue	9.79	14	12	3.83	12	2.30	-	-	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	50	49	51	76	102	22	32	13	1.69	1.19	0.48
Other Noncurrent Operating Liabilities	0.72	1.08	1.62	53	1.62	9.24	6.19	4.88	7.61	6.78	2.77
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,491	2,326	2,308	16,046	15,884	1,014	1,013	559	231	179	-68
Total Preferred & Common Equity	1,491	2,326	2,308	16,046	15,884	1,014	1,013	559	231	179	-68
Total Common Equity	1,491	2,326	2,308	16,046	15,884	1,014	1,013	559	231	179	-68
Common Stock	17,759	17,592	17,359	17,473	16,858	1,539	1,435	866	436	309	4.96
Retained Earnings	-16,230	-15,229	-15,008	-1,421	-993	-508	-409	-312	-205	-131	-72
Accumulated Other Comprehensive Income / (Loss)	-38	-37	-43	-6.29	19	-17	-13	4.09	-0.00	-0.04	-

This table presents Teladoc Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	3,444	3,529	3,524	4,321	4,328	4,316	4,309	8,104
Total Current Assets	1,602	1,609	1,547	1,486	1,387	1,321	1,287	1,288
Cash & Equivalents	1,193	1,244	1,162	1,098	1,031	959	889	900
Accounts Receivable	233	212	218	214	206	215	216	202
Inventories, net	38	37	35	32	36	34	46	59
Prepaid Expenses	138	116	131	142	115	113	136	127
Plant, Property, & Equipment, net	31	28	29	30	33	30	30	27
Total Noncurrent Assets	1,812	1,892	1,948	2,805	2,908	2,965	2,993	6,789
Goodwill	283	283	283	1,073	1,073	1,073	1,073	4,846
Intangible Assets	1,393	1,497	1,547	1,614	1,728	1,784	1,816	1,854
Other Noncurrent Operating Assets	135	112	117	118	107	108	104	89
Total Liabilities & Shareholders' Equity	3,444	3,529	3,524	4,321	4,328	4,316	4,309	8,104
Total Liabilities	2,017	2,021	2,022	2,032	2,034	2,021	2,010	2,051
Total Current Liabilities	952	931	931	389	403	383	381	411
Short-Term Debt	551	551	551	-	-	-	-	-
Accounts Payable	52	38	56	38	26	16	39	71
Accrued Expenses	219	188	174	199	193	193	185	177
Current Deferred Revenue	74	88	95	101	99	107	96	90
Current Employee Benefit Liabilities	57	66	55	51	85	67	51	63
Total Noncurrent Liabilities	1,065	1,089	1,091	1,643	1,631	1,638	1,629	1,640
Long-Term Debt	992	991	990	1,540	1,538	1,537	1,536	1,534
Capital Lease Obligations	34	37	38	40	34	37	-	41
Noncurrent Deferred Revenue	10	10	12	15	13	14	4.12	11
Noncurrent Deferred & Payable Income Tax Liabilities	24	51	51	47	44	48	51	52
Other Noncurrent Operating Liabilities	4.32	0.74	1.01	1.02	1.69	1.74	46	1.63
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,427	1,508	1,502	2,289	2,294	2,295	2,291	6,053
Total Preferred & Common Equity	1,427	1,508	1,502	2,289	2,294	2,295	2,291	6,053
Total Common Equity	1,427	1,508	1,502	2,289	2,294	2,295	2,291	6,053
Common Stock	17,787	17,726	17,689	17,638	17,535	17,477	17,410	17,300
Retained Earnings	-16,323	-16,181	-16,148	-15,311	-15,200	-15,143	-15,078	-11,198
Accumulated Other Comprehensive Income / (Loss)	-37	-37	-39	-39	-42	-39	-41	-49

This table displays calculated financial ratios and metrics derived from Teladoc Health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.26%	8.13%	18.41%	85.81%	97.71%	32.40%	79.14%	89.42%	59.15%	77.78%	118.67%
EBITDA Growth	-715.68%	100.78%	-32,611.72%	90.46%	-1,120.21%	0.30%	37.38%	-2.12%	-8.27%	-296.90%	-150.83%
EBIT Growth	-320.68%	98.21%	-5,140.62%	48.61%	-532.92%	-13.05%	20.85%	-25.87%	-27.49%	-268.22%	-158.14%
NOPAT Growth	-310.73%	98.18%	-5,039.92%	47.55%	-529.55%	-13.53%	6.02%	-20.31%	-12.33%	-268.22%	-158.14%
Net Income Growth	-354.35%	98.39%	-3,085.58%	11.61%	-390.71%	-1.83%	9.08%	-43.88%	-27.91%	-240.55%	-183.05%
EPS Growth	-338.06%	98.42%	-2,998.90%	49.07%	-288.41%	6.12%	23.83%	-10.29%	39.86%	71.61%	-27.33%
Operating Cash Flow Growth	-16.10%	84.91%	-2.42%	462.52%	-279.15%	714.59%	85.89%	33.61%	-9.95%	-315.36%	-87.66%
Free Cash Flow Firm Growth	5,966.24%	-99.87%	327,645.32%	100.01%	-22,887.30%	80.44%	27.16%	-162.45%	-150.64%	-71.18%	0.00%
Invested Capital Growth	-36.53%	-6.04%	-81.91%	-1.13%	1,621.02%	1.38%	47.41%	207.40%	209.46%	107.22%	0.00%
Revenue Q/Q Growth	-0.77%	0.88%	3.59%	9.18%	26.16%	6.50%	12.25%	20.53%	13.62%	0.00%	0.00%
EBITDA Q/Q Growth	-5.54%	102.83%	-38.96%	91.64%	-2,004.20%	10.51%	20.12%	-16.52%	2.53%	0.00%	0.00%
EBIT Q/Q Growth	-2.19%	93.93%	-38.17%	61.51%	-698.33%	3.13%	8.67%	-39.73%	-11.51%	0.00%	0.00%
NOPAT Q/Q Growth	-1.30%	93.83%	-38.20%	61.09%	-697.48%	2.72%	8.67%	-17.68%	1.75%	0.00%	0.00%
Net Income Q/Q Growth	-1.99%	94.49%	-38.53%	47.18%	-340.18%	5.57%	16.73%	-39.29%	1.00%	0.00%	0.00%
EPS Q/Q Growth	-1.73%	94.54%	-38.05%	60.38%	-274.83%	5.48%	23.83%	-33.10%	-119.23%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-13.08%	22.60%	-8.53%	4,769.96%	-167.27%	110.00%	66.74%	0.75%	9.22%	-22.04%	0.00%
Free Cash Flow Firm Q/Q Growth	4.86%	-99.54%	39.11%	100.01%	-1,347.82%	-126.74%	4.84%	-1.88%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-4.07%	-1.83%	-55.97%	-0.24%	730.56%	2.75%	-1.52%	-0.20%	-1.10%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	70.76%	70.80%	69.09%	68.01%	64.27%	66.66%	69.20%	73.58%	74.04%	72.81%	77.19%
EBITDA Margin	-25.07%	4.02%	-556.18%	-2.01%	-39.20%	-6.35%	-8.44%	-24.13%	-44.76%	-65.80%	-29.48%
Operating Margin	-39.73%	-9.55%	-567.27%	-13.07%	-46.29%	-14.54%	-16.95%	-32.32%	-50.88%	-72.09%	-34.81%
EBIT Margin	-39.96%	-9.38%	-567.30%	-12.82%	-46.34%	-14.48%	-16.95%	-38.37%	-57.75%	-72.09%	-34.81%
Profit (Net Income) Margin	-38.97%	-8.47%	-567.53%	-21.09%	-44.35%	-17.87%	-23.23%	-45.77%	-60.26%	-74.98%	-39.14%
Tax Burden Percent	100.76%	100.35%	99.97%	111.47%	84.23%	90.32%	100.12%	99.79%	100.69%	100.06%	102.33%
Interest Burden Percent	96.76%	89.96%	100.07%	147.64%	113.62%	136.65%	136.85%	119.54%	103.64%	103.94%	109.89%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-31.41%	-6.06%	-98.84%	-1.13%	-4.05%	-5.89%	-6.23%	-12.37%	-31.65%	-77.82%	-64.93%
ROIC Less NNEP Spread (ROIC-NNEP)	-109.53%	-14.39%	-931.96%	-49.30%	-45.71%	67.79%	-453.93%	-181.99%	14.25%	-48.95%	-2.37%
Return on Net Nonoperating Assets (RNNOA)	-21.06%	-3.46%	-50.01%	-1.56%	-1.70%	-3.86%	-6.13%	-14.67%	-4.60%	27.76%	0.91%
Return on Equity (ROE)	-52.46%	-9.51%	-148.85%	-2.69%	-5.74%	-9.75%	-12.35%	-27.04%	-36.25%	-50.06%	-64.01%
Cash Return on Invested Capital (CROIC)	13.28%	0.17%	39.87%	0.01%	-182.08%	-7.26%	-44.55%	-114.18%	-133.96%	-147.62%	-264.93%
Operating Return on Assets (OROA)	-25.97%	-5.59%	-123.68%	-1.47%	-5.24%	-5.12%	-6.02%	-15.87%	-26.67%	-34.69%	-16.50%
Return on Assets (ROA)	-25.32%	-5.04%	-123.73%	-2.42%	-5.01%	-6.31%	-8.25%	-18.93%	-27.83%	-36.08%	-18.55%
Return on Common Equity (ROCE)	-52.46%	-9.51%	-148.85%	-2.69%	-5.74%	-9.75%	-12.35%	-27.04%	-36.25%	-23.98%	81.21%
Return on Equity Simple (ROE_SIMPLE)	-67.15%	-9.47%	-591.90%	-2.67%	-3.05%	-9.75%	-9.58%	-19.11%	-32.15%	-32.49%	25.23%
Net Operating Profit after Tax (NOPAT)	-715	-174	-9,557	-186	-354	-56	-50	-53	-44	-39	-11
NOPAT Margin	-27.81%	-6.69%	-397.09%	-9.15%	-32.40%	-10.18%	-11.87%	-22.62%	-35.62%	-50.46%	-24.36%
Net Nonoperating Expense Percent (NNEP)	78.12%	8.33%	833.12%	48.17%	41.67%	-73.68%	447.71%	169.62%	-45.90%	-28.87%	-62.56%
Return On Investment Capital (ROIC_SIMPLE)	-23.31%	-4.45%	-246.25%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	29.24%	29.20%	30.91%	31.99%	35.73%	33.34%	30.80%	26.42%	25.96%	27.19%	22.81%
SG&A Expenses to Revenue	24.93%	26.07%	28.13%	33.88%	60.40%	41.45%	42.13%	50.48%	60.74%	78.77%	67.22%
R&D to Revenue	11.96%	13.39%	13.86%	15.34%	15.08%	11.68%	13.01%	14.77%	17.71%	18.36%	17.40%
Operating Expenses to Revenue	110.49%	80.35%	636.36%	81.08%	110.57%	81.20%	86.15%	105.90%	124.92%	144.90%	111.99%
Earnings before Interest and Taxes (EBIT)	-1,027	-244	-13,654	-261	-507	-80	-71	-90	-71	-56	-15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-644	105	-13,386	-41	-429	-35	-35	-56	-55	-51	-13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.05	1.53	1.66	0.92	1.82	5.98	3.43	3.55	3.29	3.87	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	142.61	121.82	0.00	42.64	6.46	0.00
Price to Revenue (P/Rev)	0.61	1.37	1.59	7.23	26.50	10.95	8.32	8.51	6.17	8.92	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.04	1.45	1.51	0.92	1.79	6.24	3.59	3.21	3.52	8.56	0.00
Enterprise Value to Revenue (EV/Rev)	0.72	1.55	1.86	7.39	27.12	10.86	8.16	8.87	5.99	7.49	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	38.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	6.27	11.50	23.69	77.47	0.00	201.15	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	6.09	807.89	1.16	12,776.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.06	0.68	0.68	0.08	0.09	0.46	0.41	0.37	0.19	0.15	0.49
Long-Term Debt to Equity	0.69	0.68	0.68	0.08	0.09	0.46	0.41	0.37	0.18	0.14	0.47
Financial Leverage	0.19	0.24	0.05	0.03	0.04	-0.06	0.01	0.08	-0.32	-0.57	-0.39
Leverage Ratio	2.07	1.89	1.20	1.11	1.15	1.54	1.50	1.43	1.30	1.39	1.73
Compound Leverage Factor	2.00	1.70	1.20	1.64	1.30	2.11	2.05	1.71	1.35	1.44	1.90
Debt to Total Capital	51.36%	40.47%	40.54%	7.10%	8.45%	31.46%	29.04%	27.06%	16.14%	12.91%	32.71%
Short-Term Debt to Total Capital	17.97%	0.00%	0.00%	0.00%	0.25%	0.00%	0.00%	0.00%	0.73%	0.61%	1.05%
Long-Term Debt to Total Capital	33.39%	40.47%	40.54%	7.10%	8.20%	31.46%	29.04%	27.06%	15.41%	12.30%	31.65%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	152.67%
Common Equity to Total Capital	48.64%	59.53%	59.46%	92.90%	91.55%	68.54%	70.96%	72.94%	83.86%	87.09%	-85.37%
Debt to EBITDA	-2.44	15.12	-0.12	-29.95	-3.42	-13.24	-11.76	-3.68	-0.81	-0.52	-2.02
Net Debt to EBITDA	-0.43	4.38	-0.05	-8.06	-1.58	1.47	1.81	-1.51	0.39	2.18	1.60
Long-Term Debt to EBITDA	-1.59	15.12	-0.12	-29.95	-3.32	-13.24	-11.76	-3.68	-0.77	-0.50	-1.95
Debt to NOPAT	-2.20	-9.09	-0.16	-6.59	-4.13	-8.27	-8.36	-3.93	-1.01	-0.68	-2.44
Net Debt to NOPAT	-0.39	-2.63	-0.07	-1.77	-1.91	0.92	1.29	-1.61	0.49	2.84	1.94
Long-Term Debt to NOPAT	-1.43	-9.09	-0.16	-6.59	-4.01	-8.27	-8.36	-3.93	-0.97	-0.65	-2.36
Altman Z-Score	-5.98	-3.12	-13.27	5.27	9.23	6.28	4.16	4.05	5.19	7.54	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	52.10%	226.87%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.77	3.54	3.29	3.70	3.19	6.52	8.53	3.87	3.93	8.43	5.28
Quick Ratio	1.61	3.19	2.82	3.22	2.87	6.37	8.36	3.70	3.78	8.31	5.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	302	4.98	3,855	1.18	-15,955	-69	-355	-487	-186	-74	-43
Operating Cash Flow to CapEx	236.74%	223.87%	109.57%	303.42%	-205.48%	850.97%	0.00%	-1,308.05%	-2,460.86%	-751.89%	-1,062.58%
Free Cash Flow to Firm to Interest Expense	12.70	0.22	175.69	0.01	-231.14	-2.36	-13.59	-27.86	-71.74	-33.69	-28.87
Operating Cash Flow to Interest Expense	12.34	15.71	8.63	1.55	-0.78	1.02	-0.19	-1.97	-20.04	-21.46	-7.58
Operating Cash Flow Less CapEx to Interest Expense	7.13	8.69	0.75	1.04	-1.15	0.90	-0.13	-2.12	-20.86	-24.31	-8.29
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.65	0.60	0.22	0.11	0.11	0.35	0.36	0.41	0.46	0.48	0.47
Accounts Receivable Turnover	11.91	12.16	12.68	12.02	9.67	11.01	11.83	11.41	9.50	8.16	6.36
Inventory Turnover	22.21	17.71	11.50	10.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	83.54	84.39	84.64	72.88	56.32	54.13	43.73	28.38	17.93	21.13	40.87
Accounts Payable Turnover	19.57	16.64	15.67	13.94	14.18	21.90	22.09	20.14	14.37	9.51	4.49
Days Sales Outstanding (DSO)	30.65	30.01	28.78	30.37	37.74	33.15	30.86	32.00	38.44	44.75	57.35
Days Inventory Outstanding (DIO)	16.43	20.62	31.75	36.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	18.65	21.93	23.29	26.18	25.73	16.66	16.52	18.12	25.40	38.36	81.24
Cash Conversion Cycle (CCC)	28.44	28.70	37.23	40.55	12.01	16.49	14.34	13.87	13.04	6.38	-23.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,767	2,784	2,963	16,375	16,563	962	949	644	209	68	33
Invested Capital Turnover	1.13	0.91	0.25	0.12	0.12	0.58	0.52	0.55	0.89	1.54	2.66
Increase / (Decrease) in Invested Capital	-1,017	-179	-13,413	-187	15,600	13	305	434	142	35	33
Enterprise Value (EV)	1,841	4,026	4,485	15,029	29,665	6,008	3,411	2,070	738	580	0.00
Market Capitalization	1,565	3,568	3,830	14,699	28,986	6,060	3,475	1,985	760	691	0.00
Book Value per Share	$8.66	$14.05	$14.25	$100.23	$109.57	$14.01	$14.45	$9.81	$5.02	$4.64	($34.41)
Tangible Book Value per Share	($1.30)	($2.57)	($3.72)	($2.30)	($4.96)	$0.59	$0.41	($1.75)	$0.39	$2.78	($52.74)
Total Capital	3,065	3,908	3,881	17,271	17,349	1,479	1,428	766	275	205	79
Total Debt	1,574	1,582	1,573	1,226	1,465	465	415	207	44	26	26
Total Long-Term Debt	1,024	1,582	1,573	1,226	1,423	465	415	207	42	25	25
Net Debt	276	458	655	330	679	-52	-64	85	-21	-111	-21
Capital Expenditures (CapEx)	124	156	173	64	26	3.51	-1.52	2.63	2.11	6.28	1.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-25	-55	-2.56	-1.59	-17	-19	-8.24	-6.40	-2.16	-2.51	-1.43
Debt-free Net Working Capital (DFNWC)	1,273	1,068	916	894	770	498	470	116	64	135	45
Net Working Capital (NWC)	722	1,068	916	894	727	498	470	116	62	134	44
Net Nonoperating Expense (NNE)	287	46	4,102	243	131	43	47	54	30	19	6.43
Net Nonoperating Obligations (NNO)	276	458	655	330	679	-52	-64	85	-21	-111	-21
Total Depreciation and Amortization (D&A)	383	349	268	220	78	45	36	33	16	4.86	2.32
Debt-free, Cash-free Net Working Capital to Revenue	-0.98%	-2.12%	-0.11%	-0.08%	-1.56%	-3.48%	-1.97%	-2.74%	-1.76%	-3.24%	-3.28%
Debt-free Net Working Capital to Revenue	49.55%	41.06%	38.04%	44.00%	70.34%	89.97%	112.54%	49.69%	51.68%	174.25%	103.40%
Net Working Capital to Revenue	28.11%	41.06%	38.04%	44.00%	66.45%	89.97%	112.54%	49.69%	50.05%	172.64%	101.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.87)	($1.34)	($84.60)	($2.73)	($5.36)	($1.38)	($1.47)	($1.93)	($1.75)	($2.91)	($10.25)
Adjusted Weighted Average Basic Shares Outstanding	170.56M	164.58M	161.46M	156.94M	152.70M	73.01M	70.77M	61.73M	54.24M	38.56M	1.96M
Adjusted Diluted Earnings per Share	($5.87)	($1.34)	($84.60)	($2.73)	($5.36)	($1.38)	($1.47)	($1.93)	($1.75)	($2.91)	($10.25)
Adjusted Weighted Average Diluted Shares Outstanding	170.56M	164.58M	161.46M	156.94M	152.70M	73.01M	70.77M	61.73M	54.24M	38.56M	1.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($5.36)	($1.38)	($1.47)	($1.93)	($1.75)	($2.91)	($10.25)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	173.67M	167.04M	162.62M	160.33M	90.51M	71.84M	65.84M	55.43M	42.33M	19.92M	1.96M
Normalized Net Operating Profit after Tax (NOPAT)	-146	-147	-159	-167	-293	-52	-46	-44	-36	-32	-9.55
Normalized NOPAT Margin	-5.69%	-5.66%	-6.61%	-8.23%	-26.76%	-9.34%	-11.05%	-18.66%	-29.32%	-41.93%	-21.94%
Pre Tax Income Margin	-38.67%	-8.44%	-567.69%	-18.92%	-52.65%	-19.78%	-23.20%	-45.87%	-59.85%	-74.93%	-38.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-43.14	-10.96	-622.22	-2.09	-7.34	-2.73	-2.71	-5.12	-27.48	-25.37	-10.11
NOPAT to Interest Expense	-30.02	-7.81	-435.53	-1.49	-5.14	-1.92	-1.90	-3.02	-16.95	-17.76	-7.07
EBIT Less CapEx to Interest Expense	-48.35	-17.97	-630.10	-2.60	-7.72	-2.85	-2.66	-5.27	-28.29	-28.22	-10.82
NOPAT Less CapEx to Interest Expense	-35.23	-14.83	-443.40	-2.00	-5.51	-2.04	-1.84	-3.17	-17.76	-20.61	-7.79
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.16%

This table displays calculated financial ratios and metrics derived from Teladoc Health's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-2.59%	-3.03%	-2.99%	-1.53%	2.68%	3.58%	7.99%	10.13%	11.30%	15.06%	17.20%
EBITDA Growth	-315.19%	-46.34%	63.70%	-11,826.25%	1,920.65%	101.80%	485.51%	100.21%	100.01%	-24,698.78%	-33.79%
EBIT Growth	-35.07%	-65.62%	36.61%	-1,071.45%	-21.19%	99.12%	9.26%	97.68%	98.92%	-9,016.52%	-20.26%
NOPAT Growth	-38.44%	-37.44%	31.40%	-1,074.05%	-13.00%	99.08%	9.77%	97.69%	98.84%	-9,109.86%	-18.41%
Net Income Growth	-13.58%	-67.56%	41.70%	-1,185.22%	-18.29%	99.24%	22.32%	97.90%	98.96%	-34,584.31%	12.88%
EPS Growth	-8.16%	-58.82%	45.71%	-1,130.00%	-16.67%	99.27%	22.22%	97.92%	98.99%	-77,733.33%	15.09%
Operating Cash Flow Growth	78.46%	-33.96%	4.33%	-12.35%	-32.20%	98.45%	67.56%	9.42%	141.44%	-21.22%	-17.72%
Free Cash Flow Firm Growth	715.86%	536.70%	-74.98%	-89.43%	-98.44%	-98.56%	-60.07%	-49.13%	259.52%	6,693.44%	166.63%
Invested Capital Growth	-34.65%	-36.53%	-35.04%	-34.10%	-5.73%	-6.04%	-57.86%	-57.07%	-70.24%	-81.91%	-59.01%
Revenue Q/Q Growth	-1.74%	0.00%	-0.30%	-0.57%	-2.18%	0.04%	1.20%	3.68%	-1.33%	4.30%	3.21%
EBITDA Q/Q Growth	-177.54%	-27.26%	106.68%	-5,808.58%	-80.85%	121.88%	378.80%	883.70%	100.02%	-47,406.15%	99.74%
EBIT Q/Q Growth	-112.72%	-31.77%	94.99%	-862.04%	-160.83%	49.57%	7.43%	0.48%	98.11%	-5,102.94%	97.63%
NOPAT Q/Q Growth	-150.15%	-8.59%	94.72%	-865.48%	-148.35%	45.80%	9.66%	7.08%	97.98%	-5,219.33%	97.68%
Net Income Q/Q Growth	-92.14%	-45.48%	96.03%	-922.93%	-183.45%	49.38%	12.43%	5.85%	98.18%	-5,085.46%	97.63%
EPS Q/Q Growth	-96.30%	-42.11%	96.14%	-904.08%	-188.24%	51.43%	12.50%	4.76%	98.20%	-5,088.89%	97.66%
Operating Cash Flow Q/Q Growth	-81.47%	-22.03%	24.23%	894.20%	-93.14%	23.18%	4.37%	669.09%	-79.93%	4.01%	-31.85%
Free Cash Flow Firm Q/Q Growth	-10.94%	2.13%	138.50%	276.09%	-30.50%	-95.99%	0.76%	-44.53%	-35.91%	11.47%	28.39%
Invested Capital Q/Q Growth	2.46%	-4.07%	-3.95%	-30.78%	-0.48%	-1.83%	-2.56%	-0.97%	-0.81%	-55.97%	-0.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	68.73%	70.50%	71.94%	70.73%	69.89%	70.72%	71.83%	70.79%	69.79%	70.38%	69.64%
EBITDA Margin	-4.45%	5.64%	7.75%	-115.63%	2.01%	10.19%	4.59%	0.97%	0.10%	-586.13%	-1.29%
Operating Margin	-19.16%	-7.53%	-6.93%	-130.93%	-13.48%	-5.31%	-9.80%	-10.98%	-12.25%	-598.32%	-11.73%
EBIT Margin	-18.78%	-8.67%	-6.58%	-131.02%	-13.54%	-5.08%	-10.07%	-11.01%	-11.47%	-598.05%	-11.99%
Profit (Net Income) Margin	-14.78%	-7.56%	-5.20%	-130.39%	-12.67%	-4.37%	-8.64%	-9.99%	-11.00%	-597.46%	-12.02%
Tax Burden Percent	83.59%	100.49%	102.40%	100.47%	103.40%	113.85%	95.83%	98.56%	100.99%	99.95%	98.43%
Interest Burden Percent	94.15%	86.71%	77.07%	99.06%	90.52%	75.65%	89.54%	92.04%	94.95%	99.95%	101.84%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-14.95%	-5.95%	-5.37%	-99.07%	-8.66%	-3.37%	-3.70%	-4.02%	-3.31%	-104.25%	-1.65%
ROIC Less NNEP Spread (ROIC-NNEP)	-16.94%	-9.95%	-5.87%	-147.35%	-12.36%	-4.15%	-5.63%	-6.31%	-5.52%	-335.61%	-5.86%
Return on Net Nonoperating Assets (RNNOA)	-3.94%	-1.91%	-1.35%	-40.00%	-3.05%	-1.00%	-0.82%	-0.99%	-0.67%	-18.01%	-0.29%
Return on Equity (ROE)	-18.89%	-7.86%	-6.73%	-139.07%	-11.71%	-4.36%	-4.52%	-5.00%	-3.97%	-122.26%	-1.94%
Cash Return on Invested Capital (CROIC)	9.69%	13.28%	12.33%	11.30%	-0.44%	0.17%	22.43%	21.54%	31.14%	39.87%	23.95%
Operating Return on Assets (OROA)	-12.35%	-5.64%	-4.34%	-87.21%	-8.22%	-3.03%	-4.18%	-4.49%	-3.68%	-130.38%	-2.16%
Return on Assets (ROA)	-9.72%	-4.91%	-3.42%	-86.79%	-7.69%	-2.61%	-3.59%	-4.07%	-3.53%	-130.25%	-2.17%
Return on Common Equity (ROCE)	-18.89%	-7.86%	-6.73%	-139.07%	-11.71%	-4.36%	-4.52%	-5.00%	-3.97%	-122.26%	-1.94%
Return on Equity Simple (ROE_SIMPLE)	-70.94%	0.00%	-65.11%	-66.94%	-10.18%	0.00%	-174.43%	-175.06%	-307.88%	0.00%	-162.91%
Net Operating Profit after Tax (NOPAT)	-84	-34	-31	-589	-61	-25	-45	-50	-54	-2,671	-50
NOPAT Margin	-13.41%	-5.27%	-4.85%	-91.65%	-9.44%	-3.72%	-6.86%	-7.69%	-8.58%	-418.83%	-8.21%
Net Nonoperating Expense Percent (NNEP)	1.98%	4.00%	0.50%	48.28%	3.70%	0.78%	1.93%	2.30%	2.21%	231.35%	4.22%
Return On Investment Capital (ROIC_SIMPLE)	-2.81%	-1.10%	-	-	-	-0.63%	-	-	-	-68.82%	-
Cost of Revenue to Revenue	31.27%	29.50%	28.06%	29.27%	30.11%	29.28%	28.17%	29.21%	30.21%	29.62%	30.36%
SG&A Expenses to Revenue	25.66%	23.84%	25.25%	24.90%	25.70%	24.59%	25.45%	27.49%	26.80%	27.62%	27.27%
R&D to Revenue	11.12%	11.98%	11.30%	11.95%	12.60%	13.62%	12.77%	13.38%	13.82%	13.00%	13.84%
Operating Expenses to Revenue	87.89%	78.03%	78.87%	201.66%	83.38%	76.03%	81.64%	81.78%	82.04%	668.70%	81.37%
Earnings before Interest and Taxes (EBIT)	-118	-56	-42	-842	-87	-34	-67	-72	-72	-3,814	-73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-28	36	50	-743	13	67	30	6.34	0.64	-3,738	-7.87
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.97	1.05	1.04	1.10	1.09	1.53	1.34	1.81	1.84	1.66	0.68
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.54	0.61	0.61	0.64	0.95	1.37	1.19	1.64	1.70	1.59	1.76
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.98	1.04	1.03	1.08	1.08	1.45	1.27	1.64	1.65	1.51	0.71
Enterprise Value to Revenue (EV/Rev)	0.69	0.72	0.74	0.80	1.14	1.55	1.40	1.88	1.97	1.86	2.05
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	24.93	38.48	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	5.87	6.27	5.64	6.22	8.62	11.50	12.64	19.59	20.75	23.69	23.07
Enterprise Value to Free Cash Flow (EV/FCFF)	7.96	6.09	6.61	7.60	0.00	807.89	3.36	4.56	2.44	1.16	1.72
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.11	1.06	1.05	1.05	0.69	0.68	0.69	0.69	0.67	0.68	0.26
Long-Term Debt to Equity	0.72	0.69	0.68	0.68	0.69	0.68	0.69	0.69	0.67	0.68	0.26
Financial Leverage	0.23	0.19	0.23	0.27	0.25	0.24	0.15	0.16	0.12	0.05	0.05
Leverage Ratio	2.09	2.07	2.07	2.06	1.88	1.89	1.49	1.48	1.35	1.20	1.17
Compound Leverage Factor	1.97	1.80	1.59	2.05	1.71	1.43	1.33	1.36	1.28	1.20	1.19
Debt to Total Capital	52.49%	51.36%	51.14%	51.23%	40.83%	40.47%	40.66%	40.68%	40.14%	40.54%	20.65%
Short-Term Debt to Total Capital	18.33%	17.97%	17.85%	17.88%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	34.16%	33.39%	33.30%	33.35%	40.83%	40.47%	40.66%	40.68%	40.14%	40.54%	20.65%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	47.51%	48.64%	48.86%	48.77%	59.17%	59.53%	59.34%	59.32%	59.86%	59.46%	79.35%
Debt to EBITDA	-2.30	-2.44	-2.59	-2.51	13.21	15.12	-0.43	-0.42	-0.23	-0.12	-0.16
Net Debt to EBITDA	-0.56	-0.43	-0.55	-0.66	4.03	4.38	-0.15	-0.16	-0.10	-0.05	-0.07
Long-Term Debt to EBITDA	-1.50	-1.59	-1.68	-1.63	13.21	15.12	-0.43	-0.42	-0.23	-0.12	-0.16
Debt to NOPAT	-2.14	-2.20	-2.24	-2.19	-8.73	-9.09	-0.56	-0.56	-0.31	-0.16	-0.23
Net Debt to NOPAT	-0.52	-0.39	-0.47	-0.58	-2.66	-2.63	-0.19	-0.22	-0.13	-0.07	-0.10
Long-Term Debt to NOPAT	-1.39	-1.43	-1.46	-1.43	-8.73	-9.09	-0.56	-0.56	-0.31	-0.16	-0.23
Altman Z-Score	-5.37	-5.07	-5.03	-5.76	-3.38	-2.96	-3.19	-2.89	-2.87	-5.80	-0.35
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.68	1.77	1.73	1.66	3.82	3.54	3.45	3.45	3.37	3.29	3.13
Quick Ratio	1.50	1.61	1.56	1.48	3.37	3.19	3.07	3.06	2.90	2.82	2.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	876	983	963	404	107	154	3,848	3,818	6,884	10,742	9,637
Operating Cash Flow to CapEx	50.40%	289.78%	353.71%	319.60%	25.12%	356.32%	280.50%	276.68%	28.84%	121.63%	145.87%
Free Cash Flow to Firm to Interest Expense	151.87	0.00	170.07	0.00	19.00	27.88	681.46	654.40	1,307.96	2,259.97	1,567.17
Operating Cash Flow to Interest Expense	2.76	0.00	19.47	0.00	1.58	23.49	18.70	17.34	2.50	13.79	10.25
Operating Cash Flow Less CapEx to Interest Expense	-2.72	0.00	13.96	0.00	-4.71	16.90	12.04	11.07	-6.17	2.45	3.22
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.66	0.65	0.66	0.67	0.61	0.60	0.42	0.41	0.32	0.22	0.18
Accounts Receivable Turnover	11.42	11.91	12.39	12.04	12.18	12.16	12.66	12.03	12.13	12.68	12.24
Inventory Turnover	21.44	22.21	20.73	22.10	19.58	17.71	15.86	16.01	12.83	11.50	12.56
Fixed Asset Turnover	84.83	83.54	85.02	87.38	88.28	84.39	85.76	87.58	84.89	84.64	85.58
Accounts Payable Turnover	16.80	19.57	23.69	21.11	20.04	16.64	15.61	13.67	17.37	15.67	13.85
Days Sales Outstanding (DSO)	31.97	30.65	29.45	30.33	29.98	30.01	28.83	30.33	30.10	28.78	29.83
Days Inventory Outstanding (DIO)	17.02	16.43	17.61	16.51	18.64	20.62	23.01	22.79	28.45	31.75	29.07
Days Payable Outstanding (DPO)	21.73	18.65	15.41	17.29	18.21	21.93	23.38	26.69	21.02	23.29	26.36
Cash Conversion Cycle (CCC)	27.26	28.44	31.65	29.55	30.40	28.70	28.47	26.43	37.53	37.23	32.54
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,811	1,767	1,842	1,918	2,770	2,784	2,836	2,910	2,939	2,963	6,729
Invested Capital Turnover	1.11	1.13	1.11	1.08	0.92	0.91	0.54	0.52	0.39	0.25	0.20
Increase / (Decrease) in Invested Capital	-960	-1,017	-994	-992	-168	-179	-3,893	-3,869	-6,938	-13,413	-9,687
Enterprise Value (EV)	1,766	1,841	1,906	2,074	2,981	4,026	3,608	4,759	4,859	4,485	4,774
Market Capitalization	1,382	1,565	1,572	1,659	2,500	3,568	3,066	4,144	4,212	3,830	4,098
Book Value per Share	$8.22	$8.66	$8.81	$8.86	$13.65	$14.05	$13.91	$14.02	$14.09	$14.25	$37.44
Tangible Book Value per Share	($1.44)	($1.30)	($1.59)	($1.94)	($2.38)	($2.57)	($3.08)	($3.43)	($3.68)	($3.72)	($4.01)
Total Capital	3,004	3,065	3,086	3,080	3,868	3,908	3,866	3,869	3,827	3,881	7,628
Total Debt	1,577	1,574	1,578	1,578	1,580	1,582	1,572	1,574	1,536	1,573	1,576
Total Long-Term Debt	1,026	1,024	1,027	1,027	1,580	1,582	1,572	1,574	1,536	1,573	1,576
Net Debt	383	276	334	416	482	458	542	615	648	655	676
Capital Expenditures (CapEx)	32	30	31	28	36	37	38	37	46	54	43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6.80	-25	-16	4.27	-0.51	-55	-46	-21	17	-2.56	-23
Debt-free Net Working Capital (DFNWC)	1,200	1,273	1,228	1,167	1,097	1,068	984	938	905	916	876
Net Working Capital (NWC)	649	722	677	616	1,097	1,068	984	938	905	916	876
Net Nonoperating Expense (NNE)	8.58	15	2.20	249	21	4.33	12	15	15	1,139	23
Net Nonoperating Obligations (NNO)	383	276	334	416	482	458	542	615	648	655	676
Total Depreciation and Amortization (D&A)	90	92	92	99	101	101	97	78	73	76	65
Debt-free, Cash-free Net Working Capital to Revenue	0.27%	-0.98%	-0.61%	0.16%	-0.02%	-2.12%	-1.79%	-0.83%	0.68%	-0.11%	-1.01%
Debt-free Net Working Capital to Revenue	47.01%	49.55%	47.42%	44.71%	41.90%	41.06%	38.16%	37.05%	36.64%	38.04%	37.71%
Net Working Capital to Revenue	25.44%	28.11%	26.15%	23.60%	41.90%	41.06%	38.16%	37.05%	36.64%	38.04%	37.71%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.53)	($0.27)	($0.19)	($4.92)	($0.49)	($0.17)	($0.35)	($0.40)	($0.42)	($23.35)	($0.45)
Adjusted Weighted Average Basic Shares Outstanding	174.15M	170.56M	171.50M	170.23M	167.73M	164.58M	165.12M	164.17M	162.92M	161.46M	161.73M
Adjusted Diluted Earnings per Share	($0.53)	($0.27)	($0.19)	($4.92)	($0.49)	($0.17)	($0.35)	($0.40)	($0.42)	($23.35)	($0.45)
Adjusted Weighted Average Diluted Shares Outstanding	174.15M	170.56M	171.50M	170.23M	167.73M	164.58M	165.12M	164.17M	162.92M	161.46M	161.73M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	175.43M	173.67M	172.17M	171.22M	169.59M	167.04M	165.56M	164.95M	163.67M	162.62M	161.93M
Normalized Net Operating Profit after Tax (NOPAT)	-38	-30	-28	-34	-54	-21	-41	-41	-44	-23	-47
Normalized NOPAT Margin	-6.11%	-4.61%	-4.41%	-5.36%	-8.35%	-3.17%	-6.20%	-6.33%	-7.01%	-3.55%	-7.61%
Pre Tax Income Margin	-17.68%	-7.52%	-5.07%	-129.78%	-12.26%	-3.84%	-9.02%	-10.14%	-10.89%	-597.75%	-12.21%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-20.50	0.00	-7.45	0.00	-15.49	-6.06	-11.78	-12.31	-13.72	-802.40	-11.92
NOPAT to Interest Expense	-14.64	0.00	-5.49	0.00	-10.80	-4.43	-8.02	-8.59	-10.25	-561.94	-8.17
EBIT Less CapEx to Interest Expense	-25.98	0.00	-12.95	0.00	-21.77	-12.65	-18.45	-18.58	-22.39	-813.74	-18.95
NOPAT Less CapEx to Interest Expense	-20.12	0.00	-10.99	0.00	-17.08	-11.03	-14.69	-14.86	-18.92	-573.28	-15.19
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Teladoc Health's Financials

When does Teladoc Health's fiscal year end?

According to the most recent income statement we have on file, Teladoc Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Teladoc Health's net income changed over the last 10 years?

Teladoc Health's net income appears to be on an upward trend, with a most recent value of -$1.00 billion in 2024, rising from -$17.04 million in 2014. The previous period was -$220.37 million in 2023. Find out what analysts predict for Teladoc Health in the coming months.

What is Teladoc Health's operating income?

Teladoc Health's total operating income in 2024 was -$1.02 billion, based on the following breakdown:

Total Gross Profit: $1.82 billion
Total Operating Expenses: $2.84 billion

How has Teladoc Health revenue changed over the last 10 years?

Over the last 10 years, Teladoc Health's total revenue changed from $43.53 million in 2014 to $2.57 billion in 2024, a change of 5,803.3%.

How much debt does Teladoc Health have?

Teladoc Health's total liabilities were at $2.03 billion at the end of 2024, a 2.0% decrease from 2023, and a 5,146.2% increase since 2014.

How much cash does Teladoc Health have?

In the past 10 years, Teladoc Health's cash and equivalents has ranged from $42.82 million in 2017 to $1.30 billion in 2024, and is currently $1.30 billion as of their latest financial filing in 2024.

How has Teladoc Health's book value per share changed over the last 10 years?

Over the last 10 years, Teladoc Health's book value per share changed from -34.41 in 2014 to 8.66 in 2024, a change of -125.2%.

Related Companies

This page (NYSE:TDOC) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Teladoc Health (TDOC) Financials

Frequently Asked Questions About Teladoc Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Teladoc Health (TDOC) Financials

Annual Income Statements for Teladoc Health

Quarterly Income Statements for Teladoc Health

Annual Cash Flow Statements for Teladoc Health

Quarterly Cash Flow Statements for Teladoc Health

Annual Balance Sheets for Teladoc Health

Quarterly Balance Sheets for Teladoc Health

Annual Metrics And Ratios for Teladoc Health

Quarterly Metrics And Ratios for Teladoc Health

Frequently Asked Questions About Teladoc Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools